News Releases

Date Title and Summary
Toggle Summary electroCore Announces Pricing of $18.0 Million Public Offering of Common Stock
ROCKAWAY, NJ , June 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a public offering price of $1.00 per
Toggle Summary electroCore Announces Proposed Public Offering of Common Stock
ROCKAWAY, NJ , June 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Toggle Summary electroCore Announces Publication of Study on the Effect of non-invasive Vagus Nerve Stimulation (nVNS) on Cognitive Performance Caused by Sleep Deprivation
ROCKAWAY, NJ , June 24, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper on June 10, 2021 , entitled “Effects of Transcutaneous Vagal Nerve Stimulation (tVNS/nVNS) on Cognitive
Toggle Summary electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China
ROCKAWAY, NJ , June 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Kromax International Corporation to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive
Toggle Summary electroCore to Join Russell Microcap® Index
ROCKAWAY, NJ , June 16, 2021 (GLOBE NEWSWIRE) --   electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap ® Index after its 2021 annual reconstitution, effective after the open of trading on
Toggle Summary electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits
ROCKAWAY, NJ , June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its available tax benefits through the New Jersey Economic Development Authority’s Technology
Toggle Summary electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’s Disease Patients
ROCKAWAY, N.J. , June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-Invasive Vagus Nerve Stimulation Improves Clinical and Molecular Biomarkers of Parkinson’s
Toggle Summary electroCore to Present at Investor Conferences in June
ROCKAWAY, NJ , May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June. The conferencing details are as follows: Summer
Toggle Summary electroCore Announces First Quarter 2021 Financial Results
Record First quarter 2021 net sales of $1.2 million , increased 64% over first quarter 2020 and 30% sequentially Company to host a conference call and webcast today, May 6, 2021 at 4:30 pm ET ROCKAWAY, N.J. , May 06, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache
ROCKAWAY, NJ , May 04, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the U.S. Department of Veterans Affairs is starting an investigator-initiated study of the use of gammaCore Sapphire TM non-invasive vagus nerve